What is Vericiguat studying for decompensated heart failure?

Vericiguat is being studied to see how it works in patients with decompensated heart failure when added to standard treatment. The trial looks at whether it affects hospital stays, deaths from heart events, and side effects. This research is sponsored by Khawaja Danish Ali and aims to improve heart failure care.

Who may be eligible for this decompensated heart failure clinical trial?

Adults aged 25 to 65 years with decompensated heart failure and a reduced heart pumping ability may be eligible. Both men and women can participate. Important factors include stable blood pressure above 100 mmHg and not using certain heart medications or devices. Please review eligibility criteria for more details.

Is there any cost to participate in this decompensated heart failure clinical trial?

Study-related care, including the study drugs and all trial visits, is provided at no cost. However, personal travel expenses to and from study visits may vary and are not guaranteed to be covered. Participants should plan accordingly.

Actively Recruiting

Phase 1

Age: 25Years - 65Years

All Genders

ID07444398

Vericiguat in Decompensated Cardiac Failure Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Led by Khawaja Danish Ali · Updated on 2026-03-02

130

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of Vericiguat compared to a placebo in patients with decompensated heart failure. This Phase 1 randomized study aims to understand how adding Vericiguat to standard medical therapy affects hospitalization rates, cardiovascular death, and side effects. Seventy patients meeting specific heart failure criteria will be enrolled from the emergency department after informed consent is obtained. Participants will be randomly assigned into two groups. One group will receive Vericiguat starting at 2.5 mg daily, with doses gradually increased to 10 mg as tolerated, alongside standard treatment with sacubitril-valsartan. The other group will receive only the standard treatment of sacubitril-valsartan. All patients will be followed in outpatient clinics for three months, during which doses will be adjusted based on blood pressure, symptoms, and clinical evaluations. Throughout the study, researchers will collect detailed patient histories and monitor outcomes including hospital admissions for heart failure, cardiovascular-related deaths, and any side effects experienced. Data will be carefully recorded during the three-month follow-up period to assess the safety and impact of combining Vericiguat with standard therapy in decompensated heart failure patients.

CONDITIONS

Brief Title

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Who Can Participate

Age: 25Years - 65Years

All Genders

Eligibility Criteria

You may qualify if you...

Patients diagnosed with decompensated heart failure with left ventricular ejection fraction 45% or less
Patients presenting with NYHA functional class III-IV symptoms or worsening class II symptoms
Elevated natriuretic peptide levels: NT-proBNP >1000 pg/mL in sinus rhythm or >1600 pg/mL in atrial fibrillation
Age between 25 and 65 years

You will not qualify if you...

Blood pressure less than 100 mmHg
Current or expected use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors
Use of intravenous inotropes or presence of implantable left ventricular assist devices

Research Team

Dr Khawaja Danish Ali, MBBS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here